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INTRODUCTION
Diabetes is usually a lifelong disease in which there
is a high level of glucose concentration in the
bloods.1 Every year, the prevalence of diabetes
mellitus (DM) increases in many countries around
the world. It is estimated that by the year 2030 the
prevalence of DM in Indonesia will reach 21.3 mil-
lion people.2 Results of Basic Health Research
(Riskesdas) in 2007, found that the proportion of
death caused by DM in the age group 45-54 years
in urban areas is the second highest at 14.7%.
Meanwhile, in rural areas DM ranks as the sixth
most common cause of death at 5.8%.2
In obstetrics and gynecology, diabetes mellitus
is a special concern. Women in the reproductive
age are affected by many chronic medical condi-
tions that have important effects on the precon-
ception health of the woman and on pregnancy
outcomes.3 The increased prevalence of DM influ-
ence outcome of pregnancy and choice of contra-
ception after delivery.
In Indonesia, the number of contraceptive users
is quite high. National Socioeconomic Survey (Su-
senas) in 2004 showed that the contraception
prevalence rate was 56.71% in Indonesia. This
means that one in two couples of childbearing age
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in Indonesia in 2004 was using a form contracep-
tive. The difference of contraceptive prevalence
rate in urban and rural areas is very small, which
shows that the approach strategy of family plan-
ning programs in urban and rural areas is almost
equal.4 Nowadays, the estimated Contraceptive
Prevalence Rate (CPR) or the number of contra-
ceptive users in Indonesia has reached 62%. The
types of contraception utilized include injection
(50.46%), oral contraceptive (27.94%), intraute-
rine device (IUD) (6.61%), implant (6.87 %), tubal
ligation (1.5%), condom (6.47%), and vasectomy
(0.34%).5 The majority of women will select and
pay out-of-pocket for the various methods of avail-
able contraception. This is because the different
methods of contraception chosen have different ef-
fectiveness. Planning contraceptive use for women
with DM who still have full reproductive capacity
is very important, and the safety of different types
of contraception in comparison with the risk DM
in pregnancy must be considered during counsel-
ing.6
DIABETES MELLITUS
According to WHO (2006) DM is a metabolic dis-
order characterized by high levels of sugar in the
blood, also called hyperglycemia, with impaired
metabolism of carbohydrates, fats and proteins
caused by impairment in insulin production and
non-optimal action of insulin.1,7 The normal blood
glucose levels ranged from 3.6 to 6.1 mmol/l (65-
110 mg/dl). After food consumption, the concen-
tration will range between 4.5 - 5.5 mmol/l. After
consumption of high-carbohydrate food, the con-
centration will increase to 6.5 to 7.2 mmol/l. On
the other hand, when fasting blood glucose levels
may reach 3.3 to 3.9 mmol/l.1,5,7
The WHO diagnostic criteria for diabetes include
presence of classic symptoms such as polyuria,
polydypsia, poliphagia, and weight loss with no ap-
parent reason, as well as glucose level on random
blood glucose test (RBG)  11.1 mmol/l (200mg/dl)
fasting blood glucose (FBG)  7.0 mmol/l
(126mg/dl) or Oral Glucose Tolerance Test (OGTT)
 11.1 mmol/l (200mg/dl). Random blood glucose
is the result of an examination without considering
the last meal time. Fasting means the patient does
not eat for at least 8 hours. Mean-while, OGTT con-
ducted by WHO standards, uses a glucose load
equivalent to 75 g of glucose anhidrus dissolved
into the water.7-10
Classification of DM in Pregnancy by Pyke in-
cludes 3 classes, as follows: Class I involves gesta-
tional diabetes, which is diabetes arising during
pregnancy and disappearing after delivery; Class II
or pregestational diabetes, which is diabetes start-
ing since before pregnancy and continuing after
pregnancy; Class III comprises all pregestational
complications of diabetes, which may include vas-
cular diseases such as retinopathy, nephropathy,
pelvic inflammatory disease and peripheral vascu-
lar disease. Furthermore, DM may lead to various
complications in relation to pregnancy, both for the
mother and the baby. These complications can lead
to disability or death.11
CONTRACEPTION
Contraception is an attempt to prevent the occur-
rence of pregnancy, which may be temporary or
permanent. The use of contraception is one of the
variables influencing the variable of fertility.12 The
basic of contraception selection is the intended use
of contraception itself. The purpose of the selection
of contraceptive is divided into three, namely to de-
lay pregnancy, to space pregnancy, or to end re-
productive capacity.13
In addition, the factors influencing women in
choosing a contraceptive method include indivi-
dual acceptor factors, personal health factors and
contraceptive method factors. The individual ac-
ceptor factors consist of age, lifestyle, frequency of
intercourse, the number of children desired, and
previous contraceptive experience. Personal health
factors include health status, menstrual history,
family history, physical examination results, and
pelvic examination result. Contraceptive method
factors consist of effectiveness, side effects, and
cost.14
TYPES OF CONTRACEPTION
WHO has published a guideline on choosing con-
traceptive method for any women which is avai-
lable from the UK Medical Eligibility Criteria for
Contraceptive Use (UKMEC).15
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Simple Method
This method consists of periodic abstinence, calen-
dar method, basal body temperature method, cer-
vical mucus method, Sympto-Thermal method, and
coitus interruptus.14 These methods require com-
pliance and accuracy from married couples. How-
ever, the effectiveness and efficiency of these me-
thods is low. Although fertility awareness methods
can provide effective contraception to those moti-
vated to use them, little is known about the effec-
tiveness of these methods in women with chronic
disease. Women with diabetes may experience va-
riation in their menstrual cycles, which is associa-
ted with a higher failure rate for this method.6,15
With Device
This method includes the mechanical (barrier)
which consists of male condoms and intra-vaginal
barrier, and chemical (Spermisid) which consists
of a vaginal cream, vaginal foam, jelly vaginal, vagi-
nal suppositories, vaginal tablets and vaginal so-
luble films.14 These methods can be effective con-
traceptive methods when used consistently and
correctly. However, these methods typically have
the highest failure rates because they are user-de-
pendent, with efficacy rates depending on patient
adherence to recommended use.6 Therefore, to
prevent the risk of pregnancy in women with dia-
betes, proper education regarding the use of these
methods is necessary.6,15
Table 1. Guideline on Choosing contraception from UKMEC15
UKMEC categories
UKMEC 1 A condition for which there is no restriction for the use of the contraceptive method
UKMEC 2 A condition where the advantages of using the method generally outweigh the theoretical or proven risks
UKMEC 3 A condition where the theoretical or proven risks generally outweigh the advantages of using the method
Provision of a method to a woman with a  condition given a UKMEC category 3 requires expert clinical
judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually
recommended unless other methods are not available or not acceptable
UKMEC 4 A condition which represents an unacceptable health risk if the contraceptive method is used
Table 2. UKMEC Category for Women with Diabetes Mellitus15
UKMEC category recommendations on choosing contraception for women with diabetes
Diabetes CHC POP DMPA/
NET-EN
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ted in a routine setting, but with extra pre-
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1 1 1 1 1 1 1 Accept: there is no medical reason to deny
sterilization to a woman with this condition
CHC=combined oral contraception; DMPA/NET-EN=depot medroxyprogesterone acetate/norethisterone enantate; IUD=copper-bearing intrauterine de-
vice; IUS=levonorgestrel-releasing intrauterine system; POP=progestogen-only pill
In women with DM, the selection of appropriate contraceptive with UKMEC category can be seen in the
following table.
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Modern Methods
Pill
Birth control pills usually contain estrogen and
progesterone. The mechanism of the pill is to re-
place normal estrogen and progesterone produc-
tion and suppress the hormones produced by the
ovaries and the factors released by the brain so
that ovulation can be prevented. The effectiveness
of this method theoretically reaches 99% or 0.1 to
5 pregnancies per 100 women in the first year us-
age when used appropriately. But in practice it
turns out the pill failure rate is still quite high,
reaching 0.7 to 7%.14
The pill has an effect on carbohydrate metabo-
lism, although the clinical impact appears to be un-
clear.15,16 The effect of elevated glucose levels in
the blood is a result of the decreased blood glucose
tolerance.5
On the other hand, in Thailand, Suwikroma and
Jaisamrarnb suggested that low dose combination
contraceptive pill taken by women over the age of
40 years, can improve glucose tolerance and lower
fasting blood glucose levels, making it safe for
use.5,17 The combination hormonal contraception
(CHC) is now considered a safe option for women
with uncomplicated, well-controlled type 1 or type
2 diabetes (UKMEC 2). CHC is not recommended
for women with multiple cardiovascular risk fac-
tors (UKMEC 3 or 4).6,15,16
Progestin-only pills are suitable for women with
DM of any age with or without complications
(UKMEC 2). This safety rating makes these pills an
appropriate choice for individuals who have diabe-
tes with hypertension or vascular disease.15,16
Injectable Contraceptives
The most commonly available injectable contra-
ceptive is Depo-Provera, which is a progestin-only
preparation administered every 3 months. The
mechanism of action of injectable contraceptives is
by preventing ovulation, thickening the cervical
mucus, and inhibiting the cyclic development of en-
dometrium. The effectiveness of injectable contra-
ceptives is very high, with failure rate as low as 0.3
pregnancies per 100 women during the first year
of use.14
Depot medroxyprogesterone acetate (DMPA)
and norethisterone enantate (NET-EN) injections
are long-acting reversible methods, and both are
indicated for women with uncomplicated diabetes
(UKMEC 2). However, injectable contraception is
not recommended for women with diabetic com-
plications (UKMEC 3) due to concerns about pos-
sible negative impact on lipid metabolism and
change in glucose tolerance.6,15,16
Implant
The most frequently used contraceptive implants
are Norplant. Norplant is a subdermal implant con-
traceptive containing levonorgestrel (LNG) as the
active ingredient. The mechanism of action of Nor-
plant is unclear but might be the same as other
methods containing only progestin. Norplant has
the effect of preventing ovulation, thickening the
cervical mucus, and inhibiting the cyclic develop-
ment of endometrium. The effectiveness of Nor-
plant is very high, with failure rate of only 0.05 to
1 pregnancy per 100 women in the first year of
use. Norplant failure rate is <1 pregnancy per 100
women per year in the first 5 years of use. The
failure rate was lower when compared with barrier
methods, birth control pills, and IUDs.14
Norplant, comparable with other hormonal con-
traceptives containing progestin, was found to ha-
ve minimal effect on carbohydrate metabolism, im-
proves glycemic (12.3%) and insulin (37.7%) res-
ponse after oral glucose tolerance test, although
such effects were not observed clinically.16,18 Se-
veral studies have debated the effects of the use of
implants in women with DM. There have been se-
veral reports of a decrease in insulin sensitivity af-
ter use of implants. The resulting increase in rela-
tive weight associated with contraceptive use is
possibly caused by insulin resistance.16,19 The eto-
nogestrel-releasing implant is safe (UKMEC 2) for
women with DM and provides the highest efficacy
among other reversible contraceptives.6
IUDs (Intrauterine Device)
The mechanism of action is not clearly understood
but it is likely that IUDs causes changes such as the
appearance of inflammatory cells that destroys
blastocyst or spermatozoa, thus increasing the in-
hibition of implantation, as well as accelerating
movement of ovum in the fallopian tube. The effec-
tiveness of IUDs reaches 0.6 to 0.8 pregnancies per
100 women during the first year of use. IUD failure
rate is 1-3 pregnancies per 100 women per year.14
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Copper-bearing intrauterine devices are suitable
for all women with DM (UKMEC 1). IUDs offer ef-
fective contraception without hormonal or meta-
bolic side-effects and is another long-acting rever-
sible method. During the late 1970s, the possible
problem of IUDs in insulin-dependent diabetes
mellitus (IDDM) emerged. This was at a time when
the concern was that IUDs could cause pelvic in-
flammatory disease. It has since been disputed, and
IUDs are considered to be equally effective in wo-
man with and without diabetes.The levonogestrel-
releasing intrauterine system (IUS) is also suitable
choice for many women with diabetes. The IUS is
classified as UKMEC 2 because of a theoretical con-
cern that levonogestrel may influence carbohy-
drate and lipid metabolism.15,20-22
Permanent Contraception (Sterilization)
Permanent contraception is divided into two kinds
Medical Operation for Men (MOP) and Medical
Operation for Women (MOW).14 For women who
felt they have completed childbearing or are con-
fident they will never desire pregnancy, surgical
sterilization is an excellent option, especially for
women with DM because of the higher risk of preg-
nancy complication. UKMEC stipulate that in wo-
men with diabetic complications or with poorly
controlled diabetes, sterilization should be under-
taken in a specialist setting with access to experi-
enced surgical and anaesthetic staff. This is because
of the possibility of hypoglycemia or ketoacidosis,
increased risk of wound infection and delayed
healing. Prophylactic antibiotics are recommended
before surgical sterilization.6,15,20
CONCLUSION
Contraception selection for women in the repro-
ductive age with a chronic disease like DM should
be a special concern. Based on UKMEC category,
patient condition is divided into four categories.
UKMEC 1 and 2 represents conditions that allow
use of contraception with consideration on every
advantages and disadvantages of each method.
UKEC 3 represents the use of methods requiring
expert clinical judgement and not usually recom-
mended unless other methods are not available or
not acceptable. UKMEC 4 represents a condition
that is not suitable for use of a specific method of
contraception.
For DM patients without complication any type
of contraception can be used with consideration for
the advantages and disadvantages of each type of
contraception (UKMEC 1 or 2). For diabetics with
complications or multiple risk factors, in considera-
tion for contraceptive selection, hormonal contra-
ception (especially combined hormonal contracep-
tion (CHC) pill and injection method) requires
proper consideration and consultation with health
care providers (UKMEC 3 or 4).
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